Call customer care on: 0333 358 0200
Dr Ruch Karunadasa

Authored on 14 April 2026 by Dr Ruch Karunadasa,

Reviewed 14 April 2026 by Mr Adeel Arshad.

The Future of Weight Loss: What You Need to Know About the New Once-Daily Pills

The landscape of medical weight management is evolving at an unprecedented pace. Over the past few years, weekly GLP-1 injectable medications like Wegovy® (semaglutide) and Mounjaro® (tirzepatide) have transformed obesity treatment in the UK.

However, for patients who are needle-averse or looking for a more convenient option, the next major breakthrough is just around the corner: highly effective, once-daily weight loss pills.

With pharmaceutical leaders Eli Lilly and Novo Nordisk advancing their oral therapies through clinical trials, a new era of weight management is expected to reach the UK market between late 2026 and 2027.

Here is a factual overview of what to expect, how these new medications work, and how you can ensure you are first in line when they arrive.

Moving Away from Injections: How the New Pills Work

Currently, the most effective medical weight loss treatments are administered via a weekly subcutaneous injection. While highly successful, scientists have been working to formulate these complex, appetite-regulating proteins into a stable, daily tablet that can survive the digestive system.

Two major developments are leading this shift:

1. High-Dose Oral Semaglutide (Novo Nordisk)

Novo Nordisk, the creators of Wegovy, have developed a high-dose oral version of semaglutide specifically designed for weight management. Currently, oral semaglutide is only available at lower doses (up to 14mg) under the brand name Rybelsus® for type 2 diabetes.

The new, high-dose weight loss pill (tested at 25mg and 50mg) aims to offer the trusted, clinically proven results of the Wegovy injection, but in a simple daily tablet. Trial results, such as those from the OASIS programme, have shown significant weight reductions that rival the injectable formulation.

2. Orforglipron (Eli Lilly)

Eli Lilly is developing Orforglipron, a non-peptide GLP-1 receptor agonist. The primary advantage of Orforglipron is its user-friendly design. While some current oral GLP-1s require strict fasting before and after taking the tablet, Orforglipron is being engineered to have fewer dietary restrictions, making it an incredibly convenient daily option for sustained weight management.

What This Means for Patients

The introduction of these oral medications will significantly broaden the options available for treating obesity.

  • No more needles: An accessible alternative for those who experience anxiety around injections.
  • Travel and storage: Pills are generally easier to travel with and store compared to injectable pens, which often require refrigeration before use.
  • Tailored care: More options allow clinicians to better personalise your treatment plan based on your lifestyle, preferences, and clinical needs.

It is important to note that, just like current treatments, these new oral medications will be most effective when used alongside a comprehensive lifestyle plan, including a balanced diet and regular physical activity.

Join the 2026 VIP Waitlist

As these revolutionary treatments progress towards UK regulatory approval (MHRA), global demand is expected to be incredibly high.

At PrivateDoc, we are committed to keeping our patients at the forefront of medical advancements. To ensure you get priority access the moment stock lands in our UK pharmacy, we have opened an exclusive VIP Waitlist.

Why join the waitlist?

  • First access: Be at the front of the queue to consult with our clinicians about these new medications before they are widely available.
  • Stay informed: Receive the latest updates on UK approval dates, clinical data, and stock arrivals.
  • Zero commitment: Joining the list is completely free; it simply registers your interest and does not interfere with any current treatment plans.

Join the VIP Weight Loss Pill Waitlist

What to Do in the Meantime?

If you are already on a weight loss journey, you do not need to wait for these new pills to take control of your health.

Current treatments like Wegovy and Mounjaro remain highly effective, safe, and available. If you are a current PrivateDoc patient, please continue your prescribed treatment as normal. When the new oral options become available, our clinical team can help you seamlessly and safely transition your care if it is the right clinical choice for you.

If you are looking to start your weight loss journey today, you can explore our current, clinically proven treatments and see if you are eligible below.

Disclaimer & Summary

This article is for informational purposes only and does not replace individual medical advice. Availability and approvals of pipeline medications vary by country and are subject to regulatory review by the MHRA. Always consult a qualified healthcare professional before starting or changing any medical treatment.

2026 is poised to bring greater flexibility to weight management. By staying informed and working with registered UK clinicians, you can ensure your weight loss journey is safe, effective, and tailored entirely to you.

How it works

Get personalised care
02. Get personalised care

We'll provide you with a tailored treatment plan from a UK registered doctor

Get next day delivery
03. Get next day delivery

Receive genuine medication shipped discreetly to your door